ea0035p564 | Endocrine tumours and neoplasia | ECE2014
Hantel Constanze
, Lira Regia
, Ozimek Alexandra
, Frantsev Roman
, Reincke Martin
, Mussack Thomas
, Beuschlein Felix
ASA404 (Vadimezan) belongs to a class of agents with disrupting properties against tumor vasculature. Herein, putative therapeutic applicability was investigated in preclinical models for neuroendocrine tumors of the gastroenteropancreatic system (BON) and adrenocortical carcinoma (NCIh295). Upon treatment of tumor bearing mice we detected a significant disruption of microvessels, decrease in cell proliferation, increase of apoptotic cells and extensive necrosis in BON tumors ...